EEG and behavioral profile of flutroline (CP-36,584), a novel antipsychotic drug.
The pharmacologic profile of flutroline, a tetrahydro-gamma-carboline compound, predicts an anti-psychotic compound with greater potency and longer duration than established clinical antipsychotic compounds. In normal male volunteers, it elicited EEG, behavioral, and plasma prolactin release profiles similar to established antipsychotic compounds. Peak activity occurred in 4--5 h. But the clinical activity projected from these studies is one-fifth that of haloperidol. In relation to the available clinical findings, the pharmaco-EEG data are better predictors of the clinical activity of flutroline than its preclinical profile.
D000328:Adult; D017109:Akathisia, Drug-Induced; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001519:Behavior / Q000187:drug effects*; D002243:Carbolines / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D004569:Electroencephalography; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D008297:Male; D011388:Prolactin / Q000378:metabolism
D014150:Antipsychotic Agents; D002243:Carbolines; D007211:Indoles; D011388:Prolactin; D006220:Haloperidol; C026240:flutroline